Drug Profile
IDB 1031
Alternative Names: CyrtominetinLatest Information Update: 22 Aug 2007
Price :
$50
*
At a glance
- Originator Indena; Inverni della Beffa
- Class Anti-inflammatories; Expectorants; Small molecules
- Mechanism of Action Free radical scavengers; Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 30 Aug 1999 Synthélabo and Sanofi have merged to form Sanofi-Synthélabo
- 09 Sep 1996 Inverni della Beffa is developing IDB 1031 in Italy